Biora Therapeutics Inc
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-fre… Read more
Biora Therapeutics Inc (BIOR) - Total Liabilities
Latest total liabilities as of September 2024: $121.13 Million USD
Based on the latest financial reports, Biora Therapeutics Inc (BIOR) has total liabilities worth $121.13 Million USD as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biora Therapeutics Inc - Total Liabilities Trend (2018–2023)
This chart illustrates how Biora Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Biora Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Biora Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BOSTON SCIENTIFIC (BSX.SG)
STU:BSX
|
Germany | €17.12 Billion |
|
Clean & Carbon Energy S.A.
WAR:CCE
|
Poland | zł8.32 Million |
|
STERICYCLE - Dusseldorf Stock Exchang
DU:SY9
|
Germany | €2.93 Billion |
|
Quebec Rare Earth Elements Corp
PINK:QQREF
|
USA | $82.00K |
|
Clover Power PCL
BK:CV
|
Thailand | ฿2.86 Billion |
|
ERAMET - Dusseldorf Stock Exchang
DU:ER7
|
Germany | €4.34 Billion |
|
Esthetics International Group
KLSE:5081
|
Malaysia | RM103.77 Million |
Liability Composition Analysis (2018–2023)
This chart breaks down Biora Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 8.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biora Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biora Therapeutics Inc (2018–2023)
The table below shows the annual total liabilities of Biora Therapeutics Inc from 2018 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $132.64 Million | -14.87% |
| 2022-12-31 | $155.81 Million | -19.61% |
| 2021-12-31 | $193.81 Million | -25.86% |
| 2020-12-31 | $261.43 Million | +40.86% |
| 2019-12-31 | $185.60 Million | +21.02% |
| 2018-12-31 | $153.37 Million | -- |